Titan Pharmaceuticals, Inc.Titan Pharmaceuticals, Inc.Titan Pharmaceuticals, Inc.

Titan Pharmaceuticals, Inc.

No trades
See on Supercharts
Market capitalization
‪6.49 M‬USD
−7.31USD
‪−5.57 M‬USD
‪184.00 K‬USD
‪657.59 K‬
Beta (1Y)
−0.35

About Titan Pharmaceuticals, Inc.

CEO
Gim Shen Seow
Headquarters
South San Francisco
Employees (FY)
4
Founded
1992
ISIN
US8883147055
FIGI
BBG000BTGSY7
Titan Pharmaceuticals, Inc. engages in the development of therapeutics for the treatment of chronic diseases utilizing its long-term, continuous drug delivery platform, proNeura. Its lead product is probuphine, a buprenorphine implant for the maintenance treatment of opioid addiction. The company was founded by Louis R. Bucalo on February 7, 1992 and is headquartered in South San Francisco, CA.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬

See all ideas 

Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

The current price of TTNP is 7.32 USD — it has increased by 3.09% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Titan Pharmaceuticals, Inc. stocks are traded under the ticker TTNP.
Titan Pharmaceuticals, Inc. is going to release the next earnings report on May 17, 2024. Keep track of upcoming events with our Earnings Calendar.
TTNP stock is 3.00% volatile and has beta coefficient of −0.35. Check out the list of the most volatile stocks — is Titan Pharmaceuticals, Inc. there?
TTNP earnings for the last quarter are −5.60 USD per share, whereas the estimation was −17.00 USD resulting in a 67.06% surprise. The estimated earnings for the next quarter are −7.00 USD per share. See more details about Titan Pharmaceuticals, Inc. earnings.
Titan Pharmaceuticals, Inc. revenue for the last quarter amounts to ‪682.00 K‬ USD despite the estimated figure of ‪960.00 K‬ USD. In the next quarter revenue is expected to reach ‪1.13 M‬ USD.
Yes, you can track Titan Pharmaceuticals, Inc. financials in yearly and quarterly reports right on TradingView.
TTNP stock has risen by 0.89% compared to the previous week, the month change is a 7.32% rise, over the last year Titan Pharmaceuticals, Inc. has showed a 52.03% decrease.
TTNP net income for the last quarter is ‪−1.97 M‬ USD, while the quarter before that showed ‪−338.00 K‬ USD of net income which accounts for −482.84% change. Track more Titan Pharmaceuticals, Inc. financial stats to get the full picture.
Today Titan Pharmaceuticals, Inc. has the market capitalization of ‪6.49 M‬, it has increased by 22.38% over the last week.
No, TTNP doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, TTNP shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Titan Pharmaceuticals, Inc. stock right from TradingView charts — choose your broker and connect to your account.
TTNP reached its all-time high on Sep 29, 2000 with the price of 1293069.29 USD, and its all-time low was 5.00 USD and was reached on Dec 21, 2023.
See other stocks reaching their highest and lowest prices.
As of Apr 19, 2024, the company has 4.00 employees. See our rating of the largest employees — is Titan Pharmaceuticals, Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Titan Pharmaceuticals, Inc. technincal analysis shows the buy rating today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Titan Pharmaceuticals, Inc. stock shows the sell signal. See more of Titan Pharmaceuticals, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Titan Pharmaceuticals, Inc. EBITDA is ‪−7.17 M‬ USD, and current EBITDA margin is ‪−3.89 K‬%. See more stats in Titan Pharmaceuticals, Inc. financial statements.